Theravance Biopharma, Inc.
TBPH evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Market Cap:
- $885.7M
- Lead Asset:
- ampreloxetine (Phase 3)
What it means
What to watch
Prepared research question
What matters most for TBPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TBPH
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines, with its only FDA-approved product YUPELRI (revefenacin) for COPD, and a recent Phase 3 failure for ampreloxetine.
Key risk: Pipeline setback
BioSniper Score
Based on 5 of 6 signals
Market Cap
$885.7M
Cash Runway
—
Lead Asset
ampreloxetine (Phase 3)Next Catalyst
Patent_Expiry · Oct 23, 2039Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 1 catalyst for Theravance Biopharma, Inc..
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines, with its only FDA-approved product YUPELRI (revefenacin) for COPD, and a recent Phase 3 failure for ampreloxetine.
- Theravance Biopharma's only FDA-approved product is YUPELRI (revefenacin) for maintenance treatment of COPD [sec_mda · as of 2026-08-11].
- As of 2026-06-30, the company reported cash & equivalents of $219.8M, total revenue of $20.7M, and net income of -$5.9M [sec].
- In March 2026, the Phase 3 CYPRESS study for ampreloxetine (for neurogenic orthostatic hypotension in multiple system atrophy) did not meet its primary endpoint, leading to program wind-down [sec_mda · as of 2026-08-11].
- In January 2026, the company received a $25 million milestone payment from Viatris for YUPELRI achieving $250 million in U.S. net sales in 2025 [sec · filed 2026-04-28].
- In June 2025, the company sold its remaining TRELEGY royalty interest to GSK for $225 million [sec · filed 2026-04-28].
What works
- YUPELRI net sales increased 12% to $266.6 million in 2025 compared to 2024, with customer demand growing 7% [sec · filed 2026-04-28].
- The company has a strong cash position, expecting approximately $400 million in cash, cash equivalents, and marketable securities at the end of Q1 2026 from recent milestone and royalty payments [sec_mda · as of 2026-03-23].
- The company has a partnership with Viatris for YUPELRI commercialization, with a profit/loss sharing arrangement (65% Viatris, 35% Theravance) [pipeline].
What to weigh
- The ampreloxetine Phase 3 CYPRESS study failed to meet its primary endpoint, and the program is being wound down, representing a significant pipeline setback [sec_mda · as of 2026-08-11].
- The company reported a net loss of -$5.9M as of 2026-06-30 [sec].
- The company operates in an extremely competitive, rapidly changing, and heavily regulated industry [sec · filed 2026-04-28].
- The company's strategic business plan is subject to significant uncertainty and forward-looking statements may prove incorrect [sec_mda · as of 2026-03-23].
From the filings
Quoted directly from source documents.
Ampreloxetine Phase 3 study failed
“our ampreloxetine Phase 3 clinical study (CYPRESS) in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment composite score”
SEC MD&A · August 11, 2026
YUPELRI net sales growth
“total YUPELRI net sales increased by 12% to $266.6 million in 2025 compared to 2024”
SEC filings · April 28, 2026
Sale of TRELEGY royalties
“sold our remaining royalty interest in the global net sales of TRELEGY to GSK plc for $225 million”
SEC filings · April 28, 2026
Cash position expectation
“we expect to have approximately $400 million in cash, cash equivalents, and marketable securities at the end of the first quarter of 2026”
SEC MD&A · March 23, 2026
Catalyst timeline
- 2039-10-23 · Patent_Expiry · REVEFENACIN — Patent expiry for NDA210598 (YUPELRI/revefenacin); after this date, generic competition may enter the market.
Risks & what to watch (4)›
Key risks
- Pipeline setback — Ampreloxetine Phase 3 failure eliminates a key pipeline candidate, leaving YUPELRI as the only approved product [sec_mda · as of 2026-08-11].
- Net loss position — Company reported net income of -$5.9M as of 2026-06-30, indicating ongoing unprofitability [sec].
- Competitive pressure — Operates in an extremely competitive and heavily regulated industry, with YUPELRI facing competition from Spiriva HandiHaler [sec · filed 2026-04-28] [pipeline].
- Revenue concentration — YUPELRI is the sole approved product; revenue is heavily dependent on its commercial success and partnership with Viatris [pipeline].
What to watch
- YUPELRI sales performance and milestone payments from Viatris, given its 12% growth in 2025 [sec · filed 2026-04-28].
- Cash runway and deployment of the ~$400M cash position expected at end of Q1 2026 [sec_mda · as of 2026-03-23].
- Any new pipeline developments or strategic alternatives from the strategic review committee after the ampreloxetine failure [sec · filed 2026-04-28].
- Patent expiry for REVEFENACIN (YUPELRI) on 2039-10-23, which could affect long-term exclusivity [catalyst].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated October 5, 2026 · How we verify sources →
Run Theravance Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Theravance Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.62 · 0% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~4757d
0 buys · 6 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 16.3%
- Days to cover
- 5.5
- Shares short
- 5,262,895
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TBPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Theravance Biopharma, Inc.?
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines, with its only FDA-approved product YUPELRI (revefenacin) for COPD, and a recent Phase 3 failure for ampreloxetine.
What is Theravance Biopharma, Inc.'s lead drug candidate?
Theravance Biopharma, Inc.'s most advanced tracked candidate is ampreloxetine (Phase 3) for Symptomatic Neurogenic Orthostatic Hypotension.
What is Theravance Biopharma, Inc.'s next catalyst?
Theravance Biopharma, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA210598" — expected October 23, 2039.
Who is the CEO of Theravance Biopharma, Inc.?
Mr. Rick E. Winningham M.B.A. is the chief executive officer of Theravance Biopharma, Inc. (TBPH).
Where is Theravance Biopharma, Inc. headquartered?
Theravance Biopharma, Inc. (TBPH) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.